+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Influenza Medication - Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • July 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309893
The global market for Influenza Medication is estimated at US$1.7 Billion in 2023 and is projected to reach US$2 Billion by 2030, growing at a CAGR of 1.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Zanamivir segment, which is expected to reach US$123.9 Million by 2030 with a CAGR of a 1.2%. The Oseltamivir segment is also set to grow at 2.3% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $474.2 Million in 2023, and China, forecasted to grow at an impressive 2.7% CAGR to reach $359.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Influenza Medication Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Influenza Medication Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Influenza Medication Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Biostar Pharmaceuticals, Daiichi Sankyo Co., Ltd., F. Hoffmann-La Roche AG, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

  • Biostar Pharmaceuticals
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Natco Pharma Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Influenza Medication - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Influenza Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Influenza Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Influenza Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Zanamivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Zanamivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Zanamivir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Oseltamivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Oseltamivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Oseltamivir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Peramivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Peramivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Peramivir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Amantadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Amantadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Amantadine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Rimantadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Rimantadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Rimantadine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 23: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 24: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 26: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 27: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 28: World Recent Past, Current & Future Analysis for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 29: World Historic Review for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 30: World 16-Year Perspective for Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 31: World Influenza Medication Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 32: USA Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: USA Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: USA 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 35: USA Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: USA Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: USA 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
CANADA
  • Table 38: Canada Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: Canada 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 42: Canada Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: Canada 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
JAPAN
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: Japan 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 47: Japan Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 48: Japan Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: Japan 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
CHINA
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 50: China Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: China Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: China 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 53: China Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: China Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: China 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
EUROPE
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 56: Europe Recent Past, Current & Future Analysis for Influenza Medication by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Influenza Medication by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for Influenza Medication by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: Europe 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 62: Europe Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Europe Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: Europe 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
FRANCE
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 65: France Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: France Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: France 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 68: France Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: France Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: France 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
GERMANY
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 71: Germany Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: Germany 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 74: Germany Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 75: Germany Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 76: Germany 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
ITALY
  • Table 77: Italy Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 79: Italy 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 80: Italy Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 81: Italy Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 82: Italy 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 83: UK Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 84: UK Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 85: UK 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 86: UK Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 87: UK Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 88: UK 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
SPAIN
  • Table 89: Spain Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 90: Spain Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 91: Spain 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 92: Spain Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 93: Spain Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 94: Spain 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
RUSSIA
  • Table 95: Russia Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 96: Russia Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 97: Russia 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 98: Russia Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 99: Russia Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 100: Russia 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 101: Rest of Europe Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 102: Rest of Europe Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 103: Rest of Europe 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 104: Rest of Europe Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 105: Rest of Europe Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 106: Rest of Europe 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Medication by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for Influenza Medication by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 109: Asia-Pacific 16-Year Perspective for Influenza Medication by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 111: Asia-Pacific Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 112: Asia-Pacific 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
  • Table 113: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 114: Asia-Pacific Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 115: Asia-Pacific 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
AUSTRALIA
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Biostar Pharmaceuticals
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Natco Pharma Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information